The 36-month beta value for SLS is also noteworthy at 2.40. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLS is 57.60M, and at present, short sellers hold a 13.11% of that float. The average trading volume of SLS on June 28, 2024 was 1.38M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SLS) stock’s latest price update
SELLAS Life Sciences Group Inc (NASDAQ: SLS)’s stock price has plunge by -2.91relation to previous closing price of 1.14. Nevertheless, the company has seen a -9.28% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-24 that – Acute Lymphoblastic Leukemia (ALL) is the Most Common Type of Cancer in Children – – Rare Pediatric Disease Designation (RPDD) Provides Eligibility for SLS009 to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – – Past Sales of PRVs Have Averaged More Than $100 Million – NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia (ALL). “We are pleased that the FDA has granted Rare Pediatric Disease Designation to SLS009 for the treatment of pediatric ALL, the most common cancer diagnosed in children,” said Angelos Stergiou, MD, ScD h.c.
SLS’s Market Performance
SLS’s stock has fallen by -9.28% in the past week, with a monthly drop of -18.01% and a quarterly rise of 9.58%. The volatility ratio for the week is 7.64% while the volatility levels for the last 30 days are 10.46% for SELLAS Life Sciences Group Inc The simple moving average for the last 20 days is -16.78% for SLS stock, with a simple moving average of -2.08% for the last 200 days.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at -19.39% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.17% of loss for the given period.
Volatility was left at 10.46%, however, over the last 30 days, the volatility rate increased by 7.64%, as shares sank -20.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.92% lower at present.
During the last 5 trading sessions, SLS fell by -8.61%, which changed the moving average for the period of 200-days by -26.16% in comparison to the 20-day moving average, which settled at $1.3158. In addition, SELLAS Life Sciences Group Inc saw 4.42% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SLS
The total capital return value is set at -2.68. Equity return is now at value -313.39, with -133.77 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -37.51.
Currently, EBITDA for the company is -37.87 million with net debt to EBITDA at 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.49.
Conclusion
In summary, SELLAS Life Sciences Group Inc (SLS) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
